Akebia Therapeutics, Inc. Quarterly Amortization of Intangible Assets in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
Summary
Akebia Therapeutics, Inc. quarterly/annual Amortization of Intangible Assets history and growth rate from Q1 2019 to Q3 2024.
  • Akebia Therapeutics, Inc. Amortization of Intangible Assets for the quarter ending September 30, 2024 was $9M, unchanged year-over-year.
  • Akebia Therapeutics, Inc. Amortization of Intangible Assets for the twelve months ending September 30, 2024 was $36M, a 0% decline year-over-year.
  • Akebia Therapeutics, Inc. annual Amortization of Intangible Assets for 2023 was $36M, a 0% decline from 2022.
  • Akebia Therapeutics, Inc. annual Amortization of Intangible Assets for 2022 was $36M, unchanged from 2021.
  • Akebia Therapeutics, Inc. annual Amortization of Intangible Assets for 2021 was $36M, a 10.5% increase from 2020.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)
Amortization of Intangible Assets, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $36M $9M $0 0% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $36M $9M $0 0% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $36M $9.01M $0 0% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $36M $9.03M -$1K -0.01% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $36M $9M $0 0% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $36M $9M $0 0% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $36M $9.01M $0 0% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $36M $9.03M $0 0% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $36M $9M $0 0% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $36M $9M $0 0% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-28
Q1 2022 $36M $9.01M $0 0% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $36M $9.03M +$715K +8.6% Oct 1, 2021 Dec 31, 2021 10-K/A 2023-08-28
Q3 2021 $35.3M $9M +$2.9M +47.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $32.4M $9M -$100K -1.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $32.5M $9.01M -$89K -0.98% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $32.6M $8.32M -$784K -8.61% Oct 1, 2020 Dec 31, 2020 10-K/A 2023-08-28
Q3 2020 $33.4M $6.1M -$3M -33% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $36.4M $9.1M $0 0% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $36.4M $9.1M $0 0% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $36.4M $9.1M Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $9.1M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $9.1M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $9.1M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.